9.3 Mushroom Poisoning: Amatoxins, Monomethylhydrazine, Muscarine, and Coprine

Mushroom foraging has seen a dramatic resurgence, accompanied by a corresponding rise in severe and fatal mushroom intoxications. In North America, while the vast majority of mushroom exposures involve non-toxic species or self-limiting gastrointestinal irritants, misidentification of toxic species can have catastrophic consequences. Certified Specialists in Poison Information must rapidly triage callers, distinguish benign early-onset GI distress from delayed-onset cytotoxic organ failure, coordinate specific antidotal therapies, and initiate emergent liver transplant protocols.

---

Clinical Triage and the Latency Paradigm

The single most critical diagnostic determinant in evaluating wild mushroom ingestion is latency—the time elapsed between ingestion and the onset of initial gastrointestinal or systemic symptoms.

Wild Mushroom Ingestion
         │
         ▼
Onset of Initial Symptoms
         │
         ├─────────────────────────────────────────────┐
         ▼                                             ▼
Early Onset (< 2 to 6 Hours)                  Delayed Onset (> 6 to 24 Hours)
         │                                             │
         ├─ Benign GI Irritants (Chlorophyllum)        ├─ Amatoxins (Amanita phalloides, Galerina)
         ├─ Muscarinic Storm (Inocybe, Clitocybe)      │  (Triphasic: Cholera-like GI -> Liver Failure)
         ├─ Isoxazoles (Amanita muscaria, pantherina)  ├─ Gyromitrin / MMH (Gyromitra esculenta)
         ├─ Psilocybin / Hallucinogens                 │  (GABA Depletion -> Status Epilepticus)
         └─ Coprine + Ethanol (Coprinopsis)            └─ Orellanine (Cortinarius, 3–20 Days -> ATN/ARF)
         │                                             │
         ▼                                             ▼
Generally Non-Lethal; Supportive Care         POTENTIALLY LETHAL; Emergent Antidotes & ICU Admission

THE GOLDEN RULE OF MUSHROOM TRIAGE:

• Rapid Onset (< 2 to 6 hours): Almost always indicates non-lethal toxicity (benign gastrointestinal irritants, muscarine, isoxazoles, psilocybin, or coprine). Systemic organ failure is exceedingly rare.
• Delayed Onset (> 6 to 24+ hours): Must be presumed to be a deadly, cellular-destructive mushroom (amatoxins, gyromitrin, or orellanine) until definitively proven otherwise. Immediate emergency department evaluation, aggressive decontamination, and organoprotective therapies are mandatory.
• Mixed Ingestions: If a patient consumed multiple foraged species in a single meal, early-onset GI distress from a benign species can mask the simultaneous ingestion of a lethal, delayed-onset amatoxin-containing mushroom. Every patient with delayed symptoms or an unverified mixed meal requires serial hepatic and renal surveillance.

---

Group 1: Amatoxins (Cyclopeptides) and Fulminant Hepatic Failure

Amatoxins are responsible for over 90% of all mushroom-related fatalities worldwide.

Mycological Sources

• Amanita phalloides (Death Cap): Characterized by a yellowish-green to olive metallic cap, white free gills, a prominent membranous annulus (ring), and a cup-like volva (sac) at the base of the stem, often buried in forest leaf litter.
• Amanita bisporigera, A. virosa, A. verna (Destroying Angels): Pure, porcelain-white mushrooms commonly found in North American deciduous and coniferous woods.
• Galerina marginata (Autumn Skullcap): Small, brownish, wood-rotting mushrooms growing in clusters on decaying logs, frequently mistaken by foragers for hallucinogenic Psilocybe species.
• Lepiota species (e.g., Lepiota josserandii, L. brunneoincarnata): Small dapperlings containing deadly concentrations of amatoxins.

Molecular Mechanism: RNA Polymerase II Inhibition

Amatoxins are heat-stable, bicyclic octapeptides (predominantly alpha-amanitin and beta-amanitin) that resist degradation by cooking, freezing, drying, gastric acid, and proteolytic enzymes.

Amatoxin Ingestion ──> GI Absorption ──> OATP1B3 Transporter ──> Hepatocyte Uptake
                                                                           │
                                                                           ▼
                                                             Inhibition of RNA Polymerase II
                                                                           │
                                                                           ▼
                                                             Halts DNA Transcription to mRNA
                                                                           │
                                                                           ▼
                                                             Arrest of Cellular Protein Synthesis
                                                                           │
                                                                           ▼
                                                             Centrilobular Hepatic Necrosis & Apoptosis

1. Cellular Influx: Following absorption across the intestinal epithelium, amatoxins enter the portal circulation. They are avidly cleared by hepatocytes via the Organic Anion-Transporting Polypeptide 1B3 (OATP1B3) and sodium-taurocholate cotransporting polypeptide (NTCP).
2. Transcriptional Arrest: Inside the nucleoplasm, alpha-amanitin binds with high affinity directly to the bridge helix of eukaryotic RNA polymerase II. This completely blocks the translocation of RNA polymerase II along template DNA, halting the synthesis of messenger RNA (mRNA).
3. Cell Death: Without de novo mRNA transcription, synthesis of structural proteins and essential metabolic enzymes abruptly ceases. Tissues with rapid protein turnover—specifically enterocytes, hepatocytes, and renal proximal tubular epithelial cells—undergo progressive fragmentation, apoptosis, and massive centrilobular necrosis.

The Triphasic Clinical Course

Amatoxin toxicity follows a relentlessly predictable three-phase trajectory:

CRITICAL CLINICAL TRAP (THE QUIESCENT PHASE): At 24 to 36 hours post-ingestion, patients frequently experience complete symptomatic relief from their gastrointestinal misery. Discharging a patient during this 'honeymoon' phase is a fatal error. Transaminases must be checked; if transaminases or INR are climbing, fulminant hepatic necrosis is underway.

Targeted Therapeutics and Transplantation Protocols

Resuscitation requires a coordinated, aggressive multimodal medical strategy:

1. Aggressive Crystalloid Resuscitation: Administer isotonic crystalloid boluses followed by high-rate maintenance fluids (targeting urine output ≥ 100 to 200 mL/hour). Maintaining brisk renal tubular flow prevents secondary acute tubular necrosis from hypovolemia and accelerates renal excretion of unbound amatoxins.
2. Multiple-Dose Activated Charcoal (MDAC): Amatoxins undergo extensive enterohepatic recirculation, with large concentrations excreted into the biliary tract. Administer an initial charcoal dose (1 g/kg, maximum 50 g) followed by 25 to 50 g every 4 hours for 24 to 48 hours to bind amatoxins in the intestinal lumen and prevent reabsorption.
3. Silibinin (Legalon SIL / IV Milk Thistle Extract):
   • Mechanism: Silibinin is a purified silymarin flavonolignan that acts as a potent competitive inhibitor of the OATP1B3 hepatic uptake transporter. By blocking this transporter, silibinin prevents circulating amatoxins from entering hepatocytes. It also exerts strong antioxidant and radical-scavenging properties.
   • Dosing: Administer an intravenous loading dose of 5 mg/kg IV over 1 hour, followed by a continuous intravenous infusion of 20 mg/kg/day maintained for 48 to 72 hours (or until clinical and enzymatic recovery occurs).
   • Access: Intravenous silibinin is not FDA-approved; US hospitals obtain it through an emergency investigational (IND) protocol, so the poison center often helps coordinate access while other therapies start.
4. Intravenous N-Acetylcysteine (NAC): Administer high-dose IV NAC utilizing the standard or extended acetaminophen protocol (150 mg/kg loading dose, then 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours, continued as a maintenance infusion of 6.25 to 12.5 mg/kg/hour). NAC replenishes hepatic glutathione, scavenges reactive oxygen species, improves microvascular hepatic perfusion, and improved transplant-free survival in early-stage non-acetaminophen acute liver failure in a randomized trial.
5. High-Dose Penicillin G: Historically administered at 1 million units/kg/day IV (up to 24–40 million units/day) to competitively inhibit OATP1B3 and displace amatoxins from albumin binding sites. Modern toxicology favors silibinin due to superior efficacy and penicillin's risk of neurotoxicity and hyperkalemia.
6. Urgent Liver Transplant Evaluation: Contact a liver transplant center immediately upon presentation. The King's College Criteria for non-acetaminophen acute liver failure guide emergent listing for orthotopic liver transplantation:
   • INR > 6.5 (or prothrombin time > 100 seconds), regardless of encephalopathy grade, OR
   • Any three of the following five variables:
     1. Age < 10 or > 40 years
     2. Unfavorable etiology: non-A, non-B hepatitis, halothane hepatitis, or idiosyncratic drug reaction (amatoxin poisoning is not on the original list, so mushroom-specific prognostic rules are often used alongside)
     3. Jaundice-to-encephalopathy interval > 7 days
     4. Serum bilirubin > 17.5 mg/dL (> 300 μmol/L)
     5. INR > 3.5 (PT > 50 seconds)

---

Group 2: Gyromitrin and Monomethylhydrazine (MMH)

Mycological Source: Gyromitra esculenta (False Morel)

Gyromitra esculenta (false morel, beefsteak mushroom) features an irregularly lobed, brain-like or saddle-shaped reddish-brown cap with deep convolutions, contrasting with the pitted, honeycomb-like cap of the edible true morel (Morchella species). Crucially, a longitudinal cross-section reveals that true morels are completely hollow from cap to stem base, whereas false morels are solid, pithy, or stuffed with cottony fibrous tissue.

Biochemical Mechanism: Pyridoxine and GABA Depletion

Gyromitra contains the protoxin gyromitrin (acetaldehyde methylformylhydrazone), a volatile compound that readily hydrolyzes in the warm, acidic gastric environment into monomethylhydrazine (MMH). MMH is chemically identical to the hypergolic propellant used in rocket fuel.

Gyromitrin Ingestion ──> Gastric Acid Hydrolysis ──> Monomethylhydrazine (MMH)
                                                                 │
                                                                 ▼
                                              MMH Inactivates Pyridoxal Kinase
                                                                 │
                                                                 ▼
                                              Depletion of Active Pyridoxal 5'-Phosphate (PLP / B6)
                                                                 │
                                                                 ▼
                                              Inactivation of Glutamic Acid Decarboxylase (GAD)
                                                                 │
                                                                 ▼
                                              Profound Central Depletion of GABA (Inhibitory Deficit)
                                                                 │
                                                                 ▼
                                              Intractable Status Epilepticus & Neuronal Excitotoxicity

1. Inactivation of Pyridoxal 5'-Phosphate: MMH binds avidly to the enzyme pyridoxal phosphokinase, inhibiting the phosphorylation of pyridoxine into its biologically active coenzyme form, pyridoxal 5'-phosphate (PLP).
2. Arrest of GABA Synthesis: PLP is the mandatory cofactor for glutamic acid decarboxylase (GAD), the rate-limiting enzyme that synthesizes the primary inhibitory neurotransmitter gamma-aminobutyric acid (GABA) from glutamate. Depletion of active PLP halts GABA synthesis, creating an overwhelming deficit of central inhibitory neurotransmission.
3. Hepatic and Hematologic Toxicity: MMH also forms reactive methyl radicals, depletes glutathione, binds covalently to hepatic macromolecules, and oxidizes hemoglobin, producing delayed hepatic necrosis, intravascular hemolysis, and methemoglobinemia.

Clinical Course and Antidote: Intravenous Pyridoxine

• Clinical Latency: Symptoms develop after a latent period of 6 to 12 hours (range: 4 to 24 hours) with nausea, vomiting, abdominal pain, diarrhea, headache, fatigue, and muscle twitching.
• Neurological Storm: Severe toxicity advances rapidly to ataxia, nystagmus, delirium, hyperreflexia, and intractable, recurrent status epilepticus refractory to standard anticonvulsants.
• Specific Antidote Protocol (Intravenous Pyridoxine):
  • Dosing: Administer Pyridoxine (Vitamin B6) at 25 mg/kg IV (or an empiric initial dose of 5 grams IV in adults) infused over 15 to 30 minutes.
  • Mechanism: Exogenous pyridoxine bypasses the functional block, re-establishing adequate intracellular concentrations of PLP, reactivating GAD, restoring GABA synthesis, and rapidly terminating seizures.
  • Repeat Dosing: The dose may be repeated every 15 to 20 minutes if seizures persist, up to a cumulative maximum of 15 to 20 grams.
  • Supportive Therapy: Intravenous benzodiazepines (diazepam, lorazepam) should be co-administered synergistically to enhance residual GABAA receptor channel gating. Phenytoin and levetiracetam are mechanistically ineffective.

---

Group 3: Muscarinic Mushrooms (Inocybe and Clitocybe)

Mechanism: Direct Peripheral Muscarinic Agonism

Certain small woodland and lawn mushrooms—predominantly Inocybe species (fiber caps) and Clitocybe species (e.g., C. dealbata, C. rivulosa, ivory funnel caps)—contain large concentrations of pure muscarine.

CRITICAL MYCOLOGICAL MISCONCEPTION: Despite its species name, Amanita muscaria contains only negligible, trace amounts of muscarine and does NOT cause a muscarinic toxidrome. True muscarinic poisoning occurs exclusively from Inocybe and Clitocybe species.

Muscarine is a quaternary ammonium compound that acts as a direct, potent agonist at peripheral postganglionic parasympathetic muscarinic receptors (M₁, M₂, M₃). It does NOT inhibit acetylcholinesterase, does not bind nicotinic receptors, and because of its quaternary charge, does not cross the blood-brain barrier.

Manifestations and Atropine Protocol

• Onset: Extremely rapid, characteristically developing within 15 to 30 minutes (almost always < 2 hours) of ingestion.
• Toxidrome: The patient presents in a violent peripheral muscarinic storm summarized by SLUDGEM / DUMBELS: profuse diaphoresis (patients are soaked in sweat), extreme salivation, lacrimation, miosis, rhinorrhea, severe crampy abdominal pain, watery diarrhea, urinary urgency, bronchorrhea, bronchospasm, and sinus bradycardia.
• Targeted Antidote: Atropine sulfate is the specific competitive antagonist. Administer 0.5 to 1.0 mg IV in adults (pediatric: 0.02 mg/kg IV) repeated every 5 to 10 minutes until tracheobronchial secretions are dry and bronchospasm resolves. Pralidoxime (2-PAM) has zero therapeutic role because acetylcholinesterase is not inhibited.

---

Group 4: Coprine and Disulfiram-like Reactions

Coprinopsis atramentaria (Inky Cap)

Coprinopsis atramentaria (formerly Coprinus atramentarius, the "Inky Cap" or "Tippler's Bane") is a common edible mushroom found growing in clusters near decaying stumps and disturbed soil. As the mushroom matures, its cap undergoes autodigestion (deliquescence), dissolving into a thick, black, ink-like fluid containing spores.

The Ethanol Interaction and ALDH Inhibition

• Toxin: The mushroom contains coprine, a unique amino acid derivative (N5-(1-hydroxycyclopropyl)-L-glutamine). In vivo, coprine is hydrolyzed into 1-aminocyclopropanol (1-ACP).
• Biochemical Blockade: 1-ACP is a potent, irreversible inhibitor of hepatic aldehyde dehydrogenase (ALDH).
• Clinical Presentation: Ingesting the mushroom alone causes zero symptoms. However, if the patient consumes ethanol concurrently or within 2 to 72 hours (and up to 5 to 7 days) following mushroom consumption, hepatic oxidation of ethanol halts at acetaldehyde.
• The Acetaldehyde Storm: Within 15 to 30 minutes of ethanol ingestion, accumulating acetaldehyde triggers an intense disulfiram-like reaction: dramatic facial and upper torso erythema and flushing, throbbing headache, palpitations, sinus tachycardia, nausea, vomiting, diaphoresis, chest tightness, and orthostatic hypotension.
• Management: Reassure the patient that the condition is self-limiting and rarely fatal. Provide supportive care with intravenous crystalloid fluids, antiemetics, and parenteral H1/H2 blockers. Strictly warn the patient to abstain from all forms of alcohol for at least 5 to 7 days.

---

Group 5: Isoxazoles (Amanita muscaria and A. pantherina)

Ibotenic Acid and Muscimol Neurotransmission

Amanita muscaria (Fly Agaric; iconic bright red or orange cap studded with white pyramidal warts) and Amanita pantherina (Panther Cap; brown to yellowish cap with white warts) contain the toxic isoxazole derivatives ibotenic acid and muscimol.

• Ibotenic Acid: Structurally resembles glutamic acid and acts as a potent agonist at central NMDA and metabotropic glutamate receptors, producing central nervous system excitation, ataxia, agitation, and delirium.
• Muscimol: Formed in the mushroom and in vivo via the decarboxylation of ibotenic acid; structurally resembles GABA and acts as a powerful, selective agonist at GABAA receptors, inducing sedation, central nervous system depression, and coma.

Clinical Hallmarks and the Physostigmine Contraindication

• Onset: Rapid, developing within 30 minutes to 2 hours post-ingestion.
• The 'Alternating' Toxidrome: Patients classically exhibit alternating cycles of central nervous system excitation and depression: fluctuating rapidly from profound stupor, lethargy, and coma to manic excitement, agitation, confusion, and muscle twitching/myoclonus. Visual distortions are prominent, including dysmetropsia (macropsia and micropsia)—the classic 'Alice in Wonderland' syndrome where objects appear giant or tiny.

CLINICAL WARNING (PHYSOSTIGMINE IS NOT INDICATED): Because patients often have mydriasis, tachycardia, ataxia, and delirium, clinicians may mistake the picture for an anticholinergic toxidrome and consider physostigmine. The isoxazole syndrome is driven by glutamate and GABA receptor effects rather than muscarinic blockade, so physostigmine offers no benefit and adds cholinergic risk. Management is supportive with intravenous fluids and titrated benzodiazepines for severe agitation.

Other Mushroom Groups on the CSPI Topic List

Group 6: Psilocybin ("Magic") Mushrooms

Psilocybe, Panaeolus, and related "magic mushrooms" contain psilocybin, which is dephosphorylated to psilocin, a serotonin 5-HT2A agonist.

• Onset: 20 to 60 minutes; effects last 4 to 6 hours.
• Features: Visual distortions and hallucinations, euphoria or anxiety ("bad trip"), mydriasis, tachycardia, nausea. Children may develop fever and seizures.
• Management: Calm, low-stimulus setting; benzodiazepines for severe agitation. Physical complications are uncommon in adults.
• The key trap: Foragers hunting "magic mushrooms" can pick small brown Galerina species that contain amatoxins. Delayed GI symptoms after a psilocybin hunt should prompt amatoxin evaluation.

Group 7: Gastrointestinal Irritant Mushrooms

The largest group of mushroom exposures involves GI irritants such as Chlorophyllum molybdites (the green-spored lawn mushroom), Omphalotus (jack-o'-lantern), and many Agaricus, Russula, and Lactarius species.

• Onset: Usually within 30 minutes to 3 hours.
• Features: Nausea, vomiting, cramping, and diarrhea; occasionally marked dehydration in children and older adults.
• Management: Oral or IV fluids and antiemetics; symptoms usually resolve within 24 hours.
• Triage rule: Early onset is reassuring only if the entire meal is identified. Mixed wild meals still need follow-up for delayed hepatic or renal toxicity.

Group 8: Orellanine (Cortinarius)

Cortinarius orellanus and C. rubellus contain orellanine, a delayed nephrotoxin.

• Onset: GI symptoms after 1 to 3 days; kidney injury appears 3 to 20 days after ingestion.
• Features: Thirst, polyuria then oliguria, flank pain, and tubulointerstitial nephritis progressing to acute kidney injury.
• Management: Supportive care and hemodialysis; some patients need chronic dialysis or kidney transplantation. There is no antidote.